Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 73

Similar articles for PubMed (Select 23670235)

1.

Preclinical discovery of candidate genes to guide pharmacogenetics during phase I development: the example of the novel anticancer agent ABT-751.

Innocenti F, Ramírez J, Obel J, Xiong J, Mirkov S, Chiu YL, Katz DA, Carr RA, Zhang W, Das S, Adjei A, Moyer AM, Chen PX, Krivoshik A, Medina D, Gordon GB, Ratain MJ, Sahelijo L, Weinshilboum RM, Fleming GF, Bhathena A.

Pharmacogenet Genomics. 2013 Jul;23(7):374-81. doi: 10.1097/FPC.0b013e3283623e81.

2.

Epirubicin glucuronidation is catalyzed by human UDP-glucuronosyltransferase 2B7.

Innocenti F, Iyer L, Ramírez J, Green MD, Ratain MJ.

Drug Metab Dispos. 2001 May;29(5):686-92.

3.

Sulfotransferase gene copy number variation: pharmacogenetics and function.

Hebbring SJ, Moyer AM, Weinshilboum RM.

Cytogenet Genome Res. 2008;123(1-4):205-10. doi: 10.1159/000184710. Epub 2009 Mar 11. Review.

4.

Phase II metabolism of hesperetin by individual UDP-glucuronosyltransferases and sulfotransferases and rat and human tissue samples.

Brand W, Boersma MG, Bik H, Hoek-van den Hil EF, Vervoort J, Barron D, Meinl W, Glatt H, Williamson G, van Bladeren PJ, Rietjens IM.

Drug Metab Dispos. 2010 Apr;38(4):617-25. doi: 10.1124/dmd.109.031047. Epub 2010 Jan 7.

5.

Olanzapine metabolism and the significance of UGT1A448V and UGT2B1067Y variants.

Erickson-Ridout KK, Zhu J, Lazarus P.

Pharmacogenet Genomics. 2011 Sep;21(9):539-51. doi: 10.1097/FPC.0b013e328348c76b.

PMID:
21750471
6.
7.

Associations between polymorphisms in glucuronidation and sulfation enzymes and mammographic breast density in premenopausal women in the United States.

Yong M, Schwartz SM, Atkinson C, Makar KW, Thomas SS, Newton KM, Aiello Bowles EJ, Holt VL, Leisenring WM, Lampe JW.

Cancer Epidemiol Biomarkers Prev. 2010 Feb;19(2):537-46. doi: 10.1158/1055-9965.EPI-09-0898.

8.

Pharmacogenetic impact of UDP-glucuronosyltransferase metabolic pathway and multidrug resistance-associated protein 2 transport pathway on mycophenolic acid in thoracic transplant recipients: an exploratory study.

Ting LS, Benoit-Biancamano MO, Bernard O, Riggs KW, Guillemette C, Ensom MH.

Pharmacotherapy. 2010 Nov;30(11):1097-108. doi: 10.1592/phco.30.11.1097.

PMID:
20973683
9.

Genetic polymorphisms of drug-metabolising enzymes and drug transporters in the chemotherapeutic treatment of cancer.

Bosch TM, Meijerman I, Beijnen JH, Schellens JH.

Clin Pharmacokinet. 2006;45(3):253-85. Review.

PMID:
16509759
10.

Variability in UDP-glucuronosyltransferase genes and morphine metabolism: observations from a cross-sectional multicenter study in advanced cancer patients with pain.

Fladvad T, Klepstad P, Langaas M, Dale O, Kaasa S, Caraceni A, Skorpen F.

Pharmacogenet Genomics. 2013 Mar;23(3):117-26. doi: 10.1097/FPC.0b013e32835ce485.

PMID:
23277092
11.

Cancer and molecular biomarkers of phase 2.

Dalhoff K, Buus Jensen K, Enghusen Poulsen H.

Methods Enzymol. 2005;400:618-27. Review.

PMID:
16399374
12.

The pharmacokinetics and safety of ABT-751, a novel, orally bioavailable sulfonamide antimitotic agent: results of a phase 1 study.

Hande KR, Hagey A, Berlin J, Cai Y, Meek K, Kobayashi H, Lockhart AC, Medina D, Sosman J, Gordon GB, Rothenberg ML.

Clin Cancer Res. 2006 May 1;12(9):2834-40.

14.

Sulfation pharmacogenetics: SULT1A1 and SULT1A2 allele frequencies in Caucasian, Chinese and African-American subjects.

Carlini EJ, Raftogianis RB, Wood TC, Jin F, Zheng W, Rebbeck TR, Weinshilboum RM.

Pharmacogenetics. 2001 Feb;11(1):57-68.

PMID:
11207031
15.

Sulfation of 4-hydroxy toremifene: individual variability, isoform specificity, and contribution to toremifene pharmacogenomics.

Edavana VK, Dhakal IB, Yu X, Williams S, Kadlubar S.

Drug Metab Dispos. 2012 Jun;40(6):1210-5. doi: 10.1124/dmd.111.044040. Epub 2012 Mar 20.

16.

Morphine glucuronide-to-morphine plasma ratios are unaffected by the UGT2B7 H268Y and UGT1A1*28 polymorphisms in cancer patients on chronic morphine therapy.

Holthe M, Klepstad P, Zahlsen K, Borchgrevink PC, Hagen L, Dale O, Kaasa S, Krokan HE, Skorpen F.

Eur J Clin Pharmacol. 2002 Aug;58(5):353-6. Epub 2002 Jul 13.

PMID:
12185559
17.

First chemical synthesis and in vitro characterization of the potential human metabolites 5-o-feruloylquinic acid 4'-sulfate and 4'-O-glucuronide.

Menozzi-Smarrito C, Wong CC, Meinl W, Glatt H, Fumeaux R, Munari C, Robert F, Williamson G, Barron D.

J Agric Food Chem. 2011 May 25;59(10):5671-6. doi: 10.1021/jf200272m. Epub 2011 Apr 21.

PMID:
21417257
18.

Association between sulfotransferase 1A1 genotype and survival of breast cancer patients receiving tamoxifen therapy.

Nowell S, Sweeney C, Winters M, Stone A, Lang NP, Hutchins LF, Kadlubar FF, Ambrosone CB.

J Natl Cancer Inst. 2002 Nov 6;94(21):1635-40.

19.

Polymorphisms of UDP-glucuronosyltransferase and pharmacokinetics of irinotecan.

Ando Y, Ueoka H, Sugiyama T, Ichiki M, Shimokata K, Hasegawa Y.

Ther Drug Monit. 2002 Feb;24(1):111-6.

PMID:
11805731
20.

Influence of nonsynonymous polymorphisms of UGT1A8 and UGT2B7 metabolizing enzymes on the formation of phenolic and acyl glucuronides of mycophenolic acid.

Bernard O, Tojcic J, Journault K, Perusse L, Guillemette C.

Drug Metab Dispos. 2006 Sep;34(9):1539-45. Epub 2006 Jun 21.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk